This innovative treatment utilizes the patient’s own T cells, which are modified to express a TCR targeting melanoma-associated antigen A4 (MAGE-A4), a protein present on synovial sarcoma cells (234). This evidence concerns the gene MAGEA4 and synovial sarcoma.